Search
USFDA Guidance: Clinical Investigation Exclusivity Q&A and Responding to FDA Form 483 Observations
The U.S. Food and Drug Administration (FDA) has issued guidance documents to help pharmaceutical manufacturers understand regulatory expectations related to market exclusivity for drug products and responses to inspection findings following CGMP inspections . These guidances support transparency in regulatory processes and help industry ensure compliance with quality and development requirements. Guidance: New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug
Sharan Murugan
Mar 74 min read